Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20844680 | 1.00 | SLC6A4 (0.41) | SLC6A4TACR1IDO1CYP2D6CYP3A4 | |
| SCHEMBL20844683 | 1.00 | SLC6A4 (0.41) | SLC6A4TACR1IDO1CYP2D6CYP3A4 | |
| SCHEMBL5712566 | 0.85 | SLC6A4 (0.48) | SLC6A4ANPEPENPEPLMNA | |
| SCHEMBL11664457 | 0.82 | TACR1 (0.41) | SLC6A4TACR1IDO1CYP2D6CYP3A4 | |
| SCHEMBL20844633 | 0.80 | TACR1 (0.40) | SLC6A4TACR1IDO1CYP2D6CYP3A4 | |
| SCHEMBL7241495 | 0.80 | TACR1 (0.40) | SLC6A4TACR1IDO1CYP2D6CYP3A4 | |
| SCHEMBL27557391 | 0.79 | SLC6A3 (0.38) | SLC6A4TACR1IDO1CYP2D6CYP3A4 | |
| SCHEMBL4172487 | 0.78 | AOC3 (0.45) | SLC6A4TACR1IDO1ANPEPENPEP | |
| SCHEMBL9439972 | 0.78 | CYP3A4 (0.44) | SLC6A4CYP2D6CYP3A4SLC6A2SLC6A3 | |
| SCHEMBL20844635 | 0.78 | SLC6A4 (0.42) | SLC6A4CYP3A4ANPEPENPEPHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20180111895-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| US-9878980-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170044098-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20160279235-A1 | Heterodimers of Glutamic Acid | CITIZENS BANK, N.A. | 2016-09-29 | — | — | US | disclosed |
| US-9309193-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-8487129-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279235-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | SLC6A4 1424/4885TACR1 503/4885IDO1 2032/4885 |
| US-20120269726-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | SLC6A4 1435/4885TACR1 488/4885IDO1 2038/4885 |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | SLC6A4 1424/4885TACR1 503/4885IDO1 2032/4885 |
| US-20170044098-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | SLC6A4 1508/4885TACR1 489/4885IDO1 2175/4885 |
| US-20180111895-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | SLC6A4 1409/4885TACR1 531/4885IDO1 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.